Lumbricus rubellus extract

Drug Profile

Lumbricus rubellus extract

Alternative Names: Disolf; DLBS-1033; Lumbricus low molecular weight proteins; Red earthworm extract

Latest Information Update: 24 Feb 2017

Price : $50

At a glance

  • Originator Dexa Medica
  • Class Alternative medicine; Enzymes; Thrombolytics; Traditional-Chinese-medicine
  • Mechanism of Action Fibrin inhibitors; Fibrinogen inhibitors; Fibrinolysis stimulants; Fibrinolytic agents; Janus kinase 1 inhibitors; Matrix metalloproteinase 9 inhibitors; NF-kappa B inhibitors; Platelet aggregation inhibitors; STAT1 transcription factor inhibitors; Tumour necrosis factor alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Stroke
  • Phase II/III Acute coronary syndromes; Peripheral arterial disorders

Most Recent Events

  • 12 Feb 2017 Dexa Medica terminates a phase III trial in Stroke (Adjunctive treatment) in Indonesia (PO) (NCT02362984)
  • 01 Nov 2016 Phase-II/III clinical trials in Acute coronary syndromes in Indonesia (PO) (NCT02976701)
  • 01 Apr 2016 Dexa Medica withdraws prior to enrolment a phase-II/III trial for Myocardial infarction (Adjunctive treatment) in Indonesia (PO) (NCT02146664)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top